

Wyeth Pharmaceuticals Development Pipeline (as of May 6, 2009)

Wyeth's R&D pipeline includes novel candidate medicines across our three platforms—small molecules, vaccines, and biopharmaceuticals and we believe that many of these candidate medicines have the potential to be first-in-class, best-in-class, and/or first-in-therapy. Our development portfolio of new candidate medicines from Development Track to Registration, shown by therapeutic area and indication, is outlined below. We also have a discovery portfolio of 200 different projects and therapeutic targets.

The information shown below is current as of May 6, 2009. Changes occur frequently and we undertake no obligation to update this information.

Phase 0

Inflammation

PLA-950 (Inhaled)

Asthma

Musculoskeletal Disorders

BMP-655 (Implantable)

Surgical Repair of Tendons

Neuroscience

AAB-002 (IV)

Alzheimer's Disease

AAB-003 (IV)

Alzheimer's Disease

ACC-002 (IM)

Alzheimer's Disease

ILS-920 (IV)

Stroke

NRI-470 (oral)

Pain

SAM-760 (oral)

Alzheimer's Disease

SBI-087 (SC)*

Multiple Sclerosis

VRA-175 (oral)

Pain

Oncology

inotuzumab ozogamicin (CMC-544)*

Indolent Non-Hodgkin's Lymphoma

CME-881 (IV)

Solid Tumors

PKI-179 (Oral)

Oncology

PKI-587 (IV)

Oncology

Vaccines

*Staphylococcus aureus**

Staphylococcus aureus

* New addition since October 16, 2008 update

+ Progressed since October 16, 2008 update

Phase 1

Infectious Disease

BLI-489 (IV)+

Infectious Disease

Inflammation

AGG-523 (Oral)

ATN-103 (SC)+

ATN-103 (SC)

ILV-094 (SC)

ILV-095 (SC)+

SBI-087 (SC)

SBI-087 (SC)+

Osteoarthritis

Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis

Rheumatoid Arthritis

Psoriasis, Rheumatoid Arthritis

Psoriasis

Rheumatoid Arthritis

Lupus/Systemic Lupus Erythematosus (SLE)

Metabolic

HSD-016 (Oral)

OAP-189 (SC)

Diabetes

Obesity

Neuroscience

GSI-953 (Oral)

HTC-867 (Oral)

NSA-789 (Oral)

NSA-789 (Oral)

Alzheimer's Disease

Cognitive Impairment Associated with Schizophrenia

Cognitive Impairment Associated with Schizophrenia

Alzheimer's Disease

Vaccines

MnB rLP2086 (IM)

Meningococcal Serogroup B (Infant)

Women's Health

PRA-027 (Oral)

Uterine Fibroids

* New addition since October 16, 2008 update

+ Progressed since October 16, 2008 update

Phase 2

Infectious Disease

moxidectin (Oral Tablets)
 Tygacil® (tigecycline) (IV)
 Tygacil® (tigecycline)+

Onchocerciasis (River Blindness)
 Hospital-Acquired Pneumonia
 Pediatric Skin & Skin Structure

Inflammation

IMA-026 (SC)
 TRU-015 (IV)

Asthma
 Rheumatoid Arthritis

Metabolic

Relistor® (methylnaltrexone bromide) (Oral)

Opioid-Induced Constipation in Chronic Pain

Musculoskeletal Disorders

dibotermin alfa - CPM (BMP-2) (PC)
 dibotermin alfa - CPM (BMP-2) (Intraosseous)+

Fracture Repair
 Hip Osteoporosis

Neuroscience

ACC-001 (IM)
 bapineuzumab (AAB-001) (SC)
 Pristiq® (desvenlafaxine succinate) (Oral Tablets)
 SAM-531 (Oral)

Alzheimer's Disease
 Alzheimer's Disease
 Major Depressive Disorder (Pediatric)
 Alzheimer's Disease

vabicaserin HCl (SCA-136) (SR Capsules)

Bipolar Disorder

Oncology

bosutinib (SKI-606) (Oral)
 inotuzumab ozogamicin (CMC-544) (IV)+
 neratinib (HKI-272) (Oral)

Breast Cancer
 Diffuse Large B-cell Lymphoma /
 (Combination Therapy)
 Breast Cancer Combination Therapy

Vaccines

MnB rLP2086 (IM)

Meningococcal Serogroup B (Adolescent)

* New addition since October 16, 2008 update

+ Progressed since October 16, 2008 update

Phase 3

Infectious Disease

Tygalil® (tigecycline) (IV)

Diabetic Foot Infection

Neuroscience

bapineuzumab (AAB-001) (IV)

Alzheimer's Disease

Oncology

bosutinib (SKI-606) (Oral)

neratinib (HKI-272) (Oral)+

Torisel® (temsirolimus) (IV)

Chronic Myelogenous Leukemia

Breast Cancer Monotherapy

Renal Cell Carcinoma Combination Therapy

Vaccines

13vPnC (IM)

Invasive Pneumococcal Disease (Adult)

Women's Health

bazedoxifene/conjugated estrogens (Oral Tablets)

Menopausal Symptoms / Osteoporosis

* New addition since October 16, 2008 update

+ Progressed since October 16, 2008 update

Submitted for Registration

Hemophilia

BeneFIX® Coagulation Factor IX (Recombinant) (IV) Hemophilia B (Japan)

Inflammation

Enbrel® (etanercept) (SC) Juvenile Rheumatoid Arthritis (Japan)

Metabolic

Protonix® (pantoprazole sodium) (IV, granules)+ Gastrointestinal Reflux Disease (Pediatric)

Oncology

Torisel® (temsirolimus) (IV) Mantle Cell Lymphoma (EU)
 Torisel® (temsirolimus) (IV) Renal Cancer (Japan)

Vaccines

Prenar 13 Invasive Pneumococcal Disease (Infant)
 Prevenar® (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) (SC) Invasive Pneumococcal Disease (Infant) (Japan)

Women's Health

Pristiq® (desvenlafaxine succinate) (Oral Tablets) Menopausal Vasomotor Symptoms
 Viviant™ (bazedoxifene) (Oral Tablets) Osteoporosis

* New addition since October 16, 2008 update

+ Progressed since October 16, 2008 update

Removed from Active Status Since Last Report

Inflammation

anrukinzumab (IMA-638) (SC)
ATR-107 (SC)
ATR-107 (SC)

Asthma
Crohn's Disease
Lupus/Systemic Lupus Erythematosus (SLE)

Infectious Disease

ERB-257 (IV)
RAS-111

Sepsis
Sepsis

Neuroscience

Pristiq® (desvenlafaxine succinate) (Oral Tablets)
GSI-136 (Oral)
MMS-225 (Oral)
PAZ-417
vabicaserin HCl (SCA-136) (SR Capsules)

Fibromyalgia
Alzheimer's Disease
Multiple Sclerosis
Alzheimer's Disease
Schizophrenia

Oncology

inotuzumab ozogamicin (CMC-544)

Follicular Non-Hodgkin's Lymphoma

The statements in this document that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that any of the candidate medicines identified above will be developed successfully into commercial products. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property, and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q, and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this document are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.

Please note: Trademarks for products that have not received final regulatory approval are subject to change.